New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin

Table 4 Presentation of patients with irritable bowel syndrome -bloating

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-U 1/50/M	Gas,	GERD,	polycarbophil,	Ongoing	Resolution of symptoms
	Bloating,	osteoarthritis	saccharomyces boulardii lyo,	35 wk
	ABD Pain		polyethylene glycol 3350, prn
IBS-U	Severe ABD pain,	Hypertension,	Antidiarrheals	Discontinued after 6 wk	Unimproved
2/82/F	bloating,	atherosclerotic cardiovascular disease
	distension
IBS-U	Bloating,	Osteoporosis	denosumab,	Completed after 8 wk	Resolution of symptoms
3/62/F	distension,		rifaximin,
	ABD pain,		Low FODMAP diet
	flatulence

IBS-Bloating: Irritable bowel syndrome with bloating; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal; GERD: Gastroesophageal reflux disease.